March 27 (Reuters) - Walgreen WBA.O will pay more than $2.85 million to settle whistleblower allegations that the pharmacy overbilled Medicaid programs in Georgia and Massachusetts for generic medications, the U.S. Department of Justice said on Thursday.
The settlement partially resolves claims against the Walgreens Boots Alliance unit brought under the federal, Georgia and Massachusetts False Claims Act.
Walgreen pharmacies were accused of having from 2008 to 2023 submitted elevated "usual and customary" prices for some generic medications to the MassHealth and Georgia Medicaid programs, causing those programs to pay more for the medications than they should have.
(Reporting by Jonathan Stempel in New York)
((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。